JTCS Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cortina, J. M.
Right arrow Articles by Rabago, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cortina, J. M.
Right arrow Articles by Rabago, G.

The Journal of Thoracic and Cardiovascular Surgery, Vol 91, 174-183, Copyright © 1986 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association


ARTICLES

Comparative clinical results with Omniscience (STM1), Medtronic-Hall, and Bjork-Shiley convexo-concave (70 degrees) prostheses in mitral valve replacement

JM Cortina, J Martinell, V Artiz, J Fraile and G Rabago

The intermediate clinical results of 289 patients undergoing isolated mitral valve replacement with three different low-profile mechanical prostheses have been retrospectively analyzed and compared. Between June, 1980, and September, 1983, 70 patients received the Omniscience prosthesis, 159 patients the Medtronic-Hall valve, and 60 patients the convexo-concave 70 degree Bjork-Shiley prosthesis. Hospital mortality was 15% for the Bjork-Shiley group, 4.4% for the Medtronic-Hall group, and 7.1% for the Omniscience group. Cumulative follow-up was 88 years (mean 1.7 years) for the Bjork-Shiley, 229 years (mean 1.5 years) for the Medtronic-Hall, and 223 years (mean 3.3 years) for the Omniscience group. All patients were placed on a program of anticoagulant therapy (dicumarol) postoperatively. Actuarial survival rates (+/-SE) 2 years postoperatively were comparable for the three groups: Bjork-Shiley, 90% +/- 4.7%; Medtronic-Hall, 93% +/- 2.2%; and Omniscience, 88% +/- 4.1% (p = NS). Late mortality, expressed at linearized rates (percent patient-year +/-SE), was 3.4% +/- 1.9% for the Bjork-Shiley group, 1.7% +/- 0.8% for the Medtronic-Hall group, and 3.6% +/- 1.2% for the Omniscience group (p = NS). Actuarially determined rates of freedom from thromboembolic complications (systemic embolism and valvular thrombosis) 2 years postoperatively were 97% +/- 2.2% for the Bjork- Shiley group, 94% +/- 2.1% for the Medtronic-Hall, and 84% +/- 4.7% for the Omniscience group (p = 0.05, Omniscience versus Medtronic-Hall; p = 0.02, Omniscience versus Bjork-Shiley) The actuarial probability of being free from reoperation 2 years postoperatively was 92 +/- 3.5 for the Bjork-Shiley group, 92 +/- 2.9 for the Medtronic-Hall group, and 82 +/- 3.9 for the Omniscience group (p = 0.04). The major cause for reoperation in the Omniscience group was valve thrombosis (seven patients), yielding a linearized incidence (+/-SE) of 3.1 +/- 1.1 (p = 0.01). No statistically significant differences were obtained regarding the incidence of prosthetic infective endocarditis or perivalvular leak. Overall rates of anticoagulant-related hemorrhage were comparable for the three groups.


This article has been cited by other articles:


Home page
Card Surg AdultHome page
T. Gudbjartsson, T. Absi, and S. Aranki
Mitral Valve Replacement
Card. Surg. Adult, January 1, 2008; 3(2008): 1031 - 1068.
[Full Text]


Home page
Card Surg AdultHome page
T. Gudbjartsson, S. Aranki, and L. H. Cohn
Mechanical/Bioprosthetic Mitral Valve Replacement
Card. Surg. Adult, January 1, 2003; 2(2003): 951 - 986.
[Full Text]


Home page
Ann. Thorac. Surg.Home page
M. S. Edwards, G. B. Russell, A. F. Edwards, J. W. Hammon Jr, A. R. Cordell, and N. D. Kon
Results of valve replacement with omniscience mechanical prostheses
Ann. Thorac. Surg., September 1, 2002; 74(3): 665 - 670.
[Abstract] [Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
R. Altman
Controversies in Antithrombotic Therapy in Cardiovascular Diseases
Clinical and Applied Thrombosis/Hemostasis, January 1, 1998; 4(1): 11 - 24.
[Abstract] [PDF]


Home page
Ann. Thorac. Surg.Home page
T. E. David, V. L. Gott, L. A. Harker, G. E. Miller Jr, D. C. Naftel, A. G. G. Turpie, and C. W. Akins
Mechanical Valves
Ann. Thorac. Surg., November 1, 1996; 62(5): 1567 - 1570.
[Full Text]


Home page
Ann. Thorac. Surg.Home page
A. A. Mikhail and C. W. Akins
Omniscience Valve Evolution and Literature
Ann. Thorac. Surg., August 1, 1996; 62(2): 624 - 626.
[Full Text]


Home page
Ann. Thorac. Surg.Home page
C. W. Akins
Results With Mechanical Cardiac Valvular Prostheses
Ann. Thorac. Surg., December 1, 1995; 60(6): 1836 - 1844.
[Abstract] [Full Text]


Home page
NEJMHome page
M. H. Eckman, H. J. Levine, and S. G. Pauker
Effect of Laboratory Variation in the Prothrombin-Time Ratio on the Results of Oral Anticoagulant Therapy
N. Engl. J. Med., September 2, 1993; 329(10): 696 - 702.
[Abstract] [Full Text]


Home page
Eur. J. Cardiothorac. Surg.Home page
C.W. Akins
Review of the global experience with the Medtronic-Hall valve
Eur. J. Cardiothorac. Surg., January 1, 1992; 6(suppl_1): S68 - S74.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1986 by The American Association for Thoracic Surgery.